Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...
For Your Life on MSN15h
What seniors should know about pneumococcal vaccinesAs we are approaching winter and there is an increase in respiratory diseases, it’s also important to know about pneumococcal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback